Scientist I

Mammoth Biosciences

Mammoth Biosciences

Software Engineering
Brisbane, CA, USA
Posted 6+ months ago
OPPORTUNITY
Mammoth Biosciences is seeking a Scientist I in therapeutic genome editing.

KEY RESPONSIBILITIES

  • Initiate, direct, and perform experiments to evaluate novel genome editing systems
  • Advance the application of novel CRISPR systems for human therapeutics
  • Manage direct reports and collaborate with others on the team
  • Record, document, analyze and communicate scientific data to senior staff and team members and participate in the writing of SOPs, reports, and manuscripts for publications
  • Will supervise at least 1 employee

REQUIRED QUALIFICATIONS

  • Master’s degree in Biotechnology
  • 4 years minimum relevant industry experience in molecular biology, cell engineering, CAR-T cell therapy. Experience in IND-enabling CRISPR genome editing for human therapeutics; viral and/or non-viral delivery methods (such as AAV and LNP); characterization and optimization of CRISPR systems; working with primary T cells, HSCs, and complex cell culture systems; CAR-T cell optimization and production; and NGS to characterize CRISPR editing efficiency and specificity, also required
  • Strong communication, presentation, and data analysis skills
  • 40 hours per week: M-F: 9am-5pm
  • Must have proof of legal authority to work in the United States

BENEFITS

  • Company-paid health/vision/dental benefits
  • Unlimited vacation and generous sick time
  • Company-sponsored meals and snacks
  • Wellness, caregiver and ergonomics benefits
  • 401(k) with company matching
Base Salary Range: $127,946 - $147,000
The listed base salary range is for Mammoth employees in the Bay Area. Actual base salary will be determined by geographic work location, relevant professional experience, applicable skills, and internal equity. The base salary range for those working remotely outside of the San Francisco Bay Area may differ and will be determined by industry market data for the role and specific region.
COMPANY
Mammoth Biosciences is a biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop long-term curative therapies, as well as other applications such as decentralized precision diagnostics. Founded by CRISPR pioneer and Nobel laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington, the company’s ultracompact proteins are designed to enable in vivo gene editing in difficult to reach tissues utilizing both nuclease applications and new editing modalities beyond double stranded breaks, including base editing, gene writing, and epigenetic editing. The company is building out its pipeline of potential in vivo gene editing therapeutics and capabilities and has partnerships with leading pharmaceutical and biotechnology companies to broaden the reach of its innovative and proprietary technology. Mammoth’s deep science and industry experience, along with a robust and differentiated intellectual property portfolio, have enabled the company to further its mission to transform the lives of patients and deliver on the full promise of CRISPR technologies.
It is our policy and intent to provide equal opportunity to all persons without regard to race, color, religion, political affiliation, sex/gender (including gender expression/identity, pregnancy, childbirth and related medical conditions), marital status, registered domestic partner status, sexual orientation, age, ancestry, national origin, veteran status, disability, medical condition, genetic characteristics, and/or any other basis protected by law. This policy covers all facets of employment including, but not limited to: recruitment, selection, placement, promotions, transfers, demotions, terminations, training, and compensation.
Mammoth Biosciences requires that all employees be vaccinated against Covid-19 as a condition of at-will employment, with exceptions for medical or religious reasons in compliance with local, state, and federal law.
#EXCL-BSP